繁體版 / 簡體版
 
NEWS ROOM
/ NEWS ROOM
2018-09-07
Fountain Biopharma Inc. Granted Taiwan Patent for Cancer stem cell culture platform

Fountain Biopharma Inc. announces a platform of in vitro co-culture system for cancer-associated fibroblasts and cancer cells was received patent from Taiwan Intellectual property office (TIPO).

Title of the patent is “CANCER-ASSOCIATED FIBROBLASTS IN MAINTAINING STEMNESS OF CANCER STEM CELLS”, patent No. I634209.

This platform is an in vitro co-culture system for cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for screening drugs capable of inhibiting cancer stem cells. Also disclosed a paracrine signaling  for maintaining  cancer stemness could use to predict the drug response rate and prognosis in the cancer patients.

In the future, we could use this platform to discover the novel cancer stem cell markers, therapeutic targets and mechanism.


陕西快乐十分中奖技巧 江西麻将玩法 腾讯欢乐麻将旧版免费 北京快三走势图一定牛 王牌手游麻将辅助免费版 百度知道今晚两码中特 微信捕鱼游戏可以赚钱 吉祥棋牌app下载最新版 五常森林龙江麻将 吉林快三新玩法走势图 街机电玩捕鱼真千炮 蓝洞棋牌苹果下载安装 辽宁十一选五qq群 手机麻将作弊器软件 湖北30选5中奖结果 大圣捕鱼下载手机版 手机杭州麻将